Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Alliqua BioMedical (OTCMKTS:ADYX) Head-To-Head Survey

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Alliqua BioMedical (OTCMKTS:ADYX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Profitability

This table compares Eyepoint Pharmaceuticals and Alliqua BioMedical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-485.95%	-76.13%	-61.70%
Alliqua BioMedical	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations and price targets for Eyepoint Pharmaceuticals and Alliqua BioMedical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1	0	5	1	2.86
Alliqua BioMedical	0	0	0	0	0.00

Eyepoint Pharmaceuticals currently has a consensus target price of $30.00, suggesting a potential upside of 69.11%. Given Eyepoint Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Alliqua BioMedical.

Risk & Volatility

Eyepoint Pharmaceuticals has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500. Comparatively, Alliqua BioMedical has a beta of 2.71, indicating that its stock price is 171% more volatile than the S&P 500.

Earnings and Valuation

This table compares Eyepoint Pharmaceuticals and Alliqua BioMedical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$43.27 million	33.94	-$130.87 million	($2.99)	-5.93
Alliqua BioMedical	N/A	N/A	N/A	N/A	N/A

Alliqua BioMedical has lower revenue, but higher earnings than Eyepoint Pharmaceuticals.

Insider and Institutional Ownership

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 4.5% of Eyepoint Pharmaceuticals shares are held by insiders. Comparatively, 17.4% of Alliqua BioMedical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Eyepoint Pharmaceuticals beats Alliqua BioMedical on 6 of the 11 factors compared between the two stocks.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

About Alliqua BioMedical

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.